Answers are grounded in this paper and cite their sources.
The determination of damage and activity in the course of a disease are important matters. Monitoring damage activity is critical in the evaluation of individual patients and in evaluating treatment efficacy in clinical trials. A disease damage (severity) scale has been published for systemic sclerosis. A number of potential cytokine and other soluble protein markers of disease activity for this disease have been proposed in recent publications, reviewed here.
No takes yet. Share an insight, caveat, or question.
Thomas A. Medsger (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: